
## Xuan Gao

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7395196/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Circulating tumor DNA analyses predict progressive disease and indicate trastuzumab-resistant mechanism in advanced gastric cancer. EBioMedicine, 2019, 43, 261-269.	6.1	68
2	Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma. Oncologist, 2021, 26, e1110-e1124.	3.7	56
3	CCND1 Amplification Contributes to Immunosuppression and Is Associated With a Poor Prognosis to Immune Checkpoint Inhibitors in Solid Tumors. Frontiers in Immunology, 2020, 11, 1620.	4.8	44
4	Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application. Immunotherapy, 2021, 13, 1031-1051.	2.0	14
5	RBM10 Deficiency Is Associated With Increased Immune Activity in Lung Adenocarcinoma. Frontiers in Oncology, 2021, 11, 677826.	2.8	7
6	Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors. Frontiers in Immunology, 2022, 13, 799988.	4.8	7
7	Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade. Oncolmmunology, 2022, 11, 2025668.	4.6	6
8	Comprehensive Comparative Molecular Characterization of Young and Old Lung Cancer Patients. Frontiers in Oncology, 2021, 11, 806845.	2.8	6
9	CCND1 Amplification Profiling Identifies a Subtype of Melanoma Associated With Poor Survival and an Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 0, 13, .	4.8	6
10	Immune Subtypes in LUAD Identify Novel Tumor Microenvironment Profiles With Prognostic and Therapeutic Implications. Frontiers in Immunology, 2022, 13, .	4.8	5
11	The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer. Frontiers in Immunology, 2022, 13, 834142.	4.8	4
12	A high homologous recombination deficiency score is associated with poor survival and a non-inflamed tumor microenvironment in head and neck squamous cell carcinoma patients. Oral Oncology, 2022, 128, 105860.	1.5	4
13	The prevalence of HLAâ€I LOH in Chinese pan ancer patients and genomic features of patients harboring HLAâ€I LOH. Human Mutation, 2021, 42, 1254-1264.	2.5	2
14	An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. Journal of Oncology, 2021, 2021, 1-19.	1.3	2
15	Genomic clonal evolution correlated with phenotype and prognosis in gastric cancer. Clinical and Translational Medicine, 2022, 12, e799.	4.0	0
16	Multi-omics analysis of locally advanced esophageal cell squamous carcinoma treated with radio-chemotherapy Journal of Clinical Oncology, 2022, 40, e16106-e16106.	1.6	0